Table 1.
Baseline Characteristics of Patients with Gastric Cancer (n=7,215)
| Characteristic | WMD | PD | PCC | Mixed carcinoma | Total | p-value* |
|---|---|---|---|---|---|---|
| No. of patients | 4,064 (56.3) | 739 (10.2) | 1,625 (22.5) | 787 (10.9) | 7,215 (100) | |
| Age, yr | 65.4±10.1 | 62.6±12.5 | 54.2±12.3 | 56.8±12.7 | 61.6±12.2 | <0.001 |
| Sex | <0.001 | |||||
| Male | 3,071 (75.6) | 521 (70.5) | 790 (48.6) | 428 (54.4) | 4,810 (66.7) | |
| Female | 993 (24.4) | 218 (29.5) | 835 (51.4) | 359 (45.6) | 2,405 (33.3) | |
| Size of tumor, cm | 2.5±1.9 | 4.4±2.8 | 4.1±3.6 | 3.9±2.6 | 3.2±2.7 | <0.001 |
| Location | <0.001 | |||||
| Upper | 583 (14.3) | 204 (27.6) | 384 (23.6) | 140 (17.8) | 1,311 (18.2) | |
| Middle | 611 (15.0) | 170 (23.0) | 442 (27.2) | 178 (22.6) | 1,401 (19.4) | |
| Lower | 2,870 (70.6) | 365 (49.4) | 799 (49.2) | 469 (59.6) | 4,503 (62.4) | |
| Lauren type† | <0.001 | |||||
| Intestinal | 4,060 (99.8) | 352 (47.6) | 2 (0.1) | 181 (23.0) | 4,595 (63.7) | |
| Diffuse | 2 (0.1) | 352 (47.6) | 1,617 (99.5) | 473 (60.1) | 2,444 (33.9) | |
| Mixed | 2 (0.1) | 35 (4.7) | 6 (0.4) | 132 (16.8) | 175 (2.4) | |
| Treatment | <0.001 | |||||
| Endoscopic | 1,622 (39.9) | 40 (5.4) | 51 (3.1) | 39 (5.0) | 1,752 (24.3) | |
| Operative | 2,442 (60.1) | 699 (94.6) | 1,574 (96.9) | 748 (95.0) | 5,463 (75.7) | |
| Cancer type | <0.001 | |||||
| EGC | 3,306 (81.3) | 335 (45.3) | 981 (60.4) | 557 (70.8) | 5,179 (71.8) | |
| AGC | 758 (18.7) | 404 (54.7) | 644 (39.6) | 230 (29.2) | 2,036 (28.2) | |
| Lymphatic invasion | 819 (20.8) | 352 (50.4) | 394 (25.2) | 240 (30.6) | 1,805 (25.9) | <0.001 |
| Venous invasion | 188 (4.8) | 97 (13.9) | 173 (11.1) | 42 (5.4) | 500 (7.2) | <0.001 |
| Perineural invasion | 410 (10.4) | 252 (36.1) | 576 (36.9) | 193 (24.6) | 1,431 (20.5) | <0.001 |
| T stage‡ | <0.001 | |||||
| 1a | 2,252 (55.4) | 155 (21.0) | 647 (39.8) | 328 (41.7) | 3,382 (46.9) | |
| 1b | 1,054 (25.9) | 180 (24.4) | 334 (20.6) | 229 (29.1) | 1,797 (24.9) | |
| 2 | 284 (7.0) | 92 (12.4) | 139 (8.6) | 83 (10.5) | 598 (8.3) | |
| 3 | 310 (7.6) | 170 (23.0) | 184 (11.3) | 71 (9.0) | 735 (10.2) | |
| 4a | 113 (2.8) | 108 (14.6) | 277 (17.0) | 71 (9.0) | 569 (7.9) | |
| 4b | 51 (1.3) | 34 (4.6) | 44 (2.7) | 5 (0.6) | 134 (1.9) | |
| Node metastasis | <0.001 | |||||
| Negative | 3,424 (84.3) | 409 (55.3) | 1,112 (68.4) | 479 (60.9) | 5,424 (75.2) | |
| Positive | 640 (15.7) | 330 (44.7) | 513 (31.6) | 308 (39.1) | 1,791 (24.8) | |
| Distant metastasis | <0.001 | |||||
| Negative | 4,034 (99.3) | 712 (96.3) | 1,586 (97.6) | 777 (98.7) | 7,109 (98.5) | |
| Positive | 30 (0.7) | 27 (3.7) | 39 (2.4) | 10 (1.3) | 106 (1.5) |
Data are presented as number (%) or mean±SD.
WMD, well-moderately differentiated; PD, poorly differentiated; PCC, poorly cohesive carcinoma; EGC, early gastric cancer; AGC, advanced gastric cancer.
*The p-values were calculated by the Student t-test (for continuous variables) and chi-square test (for categorical variables); †The total number was different because unknown or missing values were excluded from the percentage calculation; ‡The clinical stage was established according to the guidelines of the 8th American Joint Committee on Cancer.